Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Lenalidomide (LMID) Significantly Enhances Circulating Serum Levels of IL-2 and IL-15 Levels, NK Expansion and Activation and NK and LAK Cytotoxicity in Children with Refractory/Recurrent Solid Tumors: A Children’s Oncology Group Phase I Consortium Report

Janet Ayello, MS, MT, Stacey L Berg, MD, Mark Krailo, PhD, Carmella van de Ven, MS, Ashish Mark Ingle, MS, Duane Lewis, Lauren Harrison, RN, Susan Blaney, MD, Peter C. Adamson, MD, Mitchell S. Cairo, MD

Blood (2008) 112 (11): 107.

https://doi.org/10.1182/blood.V112.11.107.107

Published: 2008

Journal Articles

Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children's Oncology Group

Hisaki Fujii, Geoff Cuvelier, Kevin She, Soudabeh Aslanian, Hiromi Shimizu, Amina Kariminia, Mark Krailo, Zhengjia Chen, Rob McMaster, Axel Bergman, Frederick Goldman, Stephen A. Grupp, Donna A. Wall, Andrew L. Gilman, Kirk R. Schultz

Blood (2008) 111 (6): 3276–3285.

https://doi.org/10.1182/blood-2007-08-106286

Published: 2008

Journal Articles

Inflammatory Markers and Autoantibodies That Correlate with Early and Late Onset of New Onset Pediatric Chronic Graft-Versus-Host Disease (GVHD).

Hisaki Fujii, MD, Kevin She, MSc, Soudabeh Aslanian, BSc, Hiromi Shimizu, BSc, Mark Krailo, PhD, Zhengjia Chen, MS, Frederick Goldman, MD, PhD, Donna A. Wall, MD, PhD, Andrew L. Gilman, MD, Kirk R. Schultz, MD

Blood (2006) 108 (11): 3232.

https://doi.org/10.1182/blood.V108.11.3232.3232

Published: 2006

Journal Articles

A Phase I Study of 90 Y-Ibritumomab-Tiuxetan ( 90 Y-It) in Children with Recurrent/Refractory CD20 Positive Lymphoma: A Cog Phase I Consortium Study.

Mitchell S. Cairo, MD, Erin Cooney, CPNP, Mark Krailo, PhD, Richard Belanger, MS, CHP, Sherrie L. Perkins, MD, PhD, Rashid Fawwaz, MD, Anne Angiolillo, MD, Peter Adamson, MD

Blood (2005) 106 (11): 2448.

https://doi.org/10.1182/blood.V106.11.2448.2448

Published: 2005

Journal Articles

Eosinophilia, Positive ANA, and Hypergammaglobulinemia at Presentation of Extensive Chronic GVHD in Children: A Children’s Oncology Group Study.

David A. Jacobsohn, MD, Kirk R. Schultz, MD, Frederick Goldman, MD, Donna A. Wall, MD, Mark Krailo, PhD, Zhengjia Chen, MS, Jeffrey M. Lipton, MD, PhD, Jean E. Sanders, MD, Andrew L. Gilman, MD

Blood (2005) 106 (11): 5375.

https://doi.org/10.1182/blood.V106.11.5375.5375

Published: 2005

Journal Articles

Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study

Martin A. Champagne, Renaud Capdeville, Mark Krailo, Wenchun Qu, Bin Peng, Marianne Rosamilia, Martine Therrien, Ulrike Zoellner, Susan M. Blaney, Mark Bernstein

Blood (2004) 104 (9): 2655–2660.

https://doi.org/10.1182/blood-2003-09-3032

Published: 2004

NARROW

Lenalidomide (LMID) Significantly Enhances Circulating Serum Levels of IL-2 and IL-15 Levels, NK Expansion and Activation and NK and LAK Cytotoxicity in Children with Refractory/Recurrent Solid Tumors: A Children’s Oncology Group Phase I Consortium Report

Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children's Oncology Group

Inflammatory Markers and Autoantibodies That Correlate with Early and Late Onset of New Onset Pediatric Chronic Graft-Versus-Host Disease (GVHD).

A Phase I Study of 90 Y-Ibritumomab-Tiuxetan ( 90 Y-It) in Children with Recurrent/Refractory CD20 Positive Lymphoma: A Cog Phase I Consortium Study.

Eosinophilia, Positive ANA, and Hypergammaglobulinemia at Presentation of Extensive Chronic GVHD in Children: A Children’s Oncology Group Study.

Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study

Email alerts

ASH Publications

American Society of Hematology

Lenalidomide (LMID) Significantly Enhances Circulating Serum Levels of IL-2 and IL-15 Levels, NK Expansion and Activation and NK and LAK Cytotoxicity in Children with Refractory/Recurrent Solid Tumors: A Children’s Oncology Group Phase I Consortium Report

Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children's Oncology Group

Inflammatory Markers and Autoantibodies That Correlate with Early and Late Onset of New Onset Pediatric Chronic Graft-Versus-Host Disease (GVHD).

A Phase I Study of 90 Y-Ibritumomab-Tiuxetan ( 90 Y-It) in Children with Recurrent/Refractory CD20 Positive Lymphoma: A Cog Phase I Consortium Study.

Eosinophilia, Positive ANA, and Hypergammaglobulinemia at Presentation of Extensive Chronic GVHD in Children: A Children’s Oncology Group Study.

Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only